Resistance of Candida to azoles and echinocandins worldwide
Cancers , 15 (2), 350
Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( References Damy, Thibaud et al
Otolaryngol Clin North Am 54(6):11011115 Tan WJ, Song L (2023) Role of mitochondrial dysfunction and oxidative stress in sensorineural hearing loss
Rotate sites with every dose to prevent bruising, scar tissue, and irritation